Suppr超能文献

系统评价与荟萃分析:挥发性有机化合物分析提高粪便免疫化学检测在结直肠癌检测中的应用。

Systematic review with meta-analysis: volatile organic compound analysis to improve faecal immunochemical testing in the detection of colorectal cancer.

机构信息

Coventry, UK.

Amsterdam, The Netherlands.

出版信息

Aliment Pharmacol Ther. 2021 Jul;54(1):14-23. doi: 10.1111/apt.16405. Epub 2021 May 18.

Abstract

BACKGROUND

Faecal immunochemical test (FIT) is emerging as a valid test to rule-out the presence of colorectal cancer (CRC). However, the accuracy of FIT is dependent on the cut-off applied. An additional low-cost test could improve further detection of CRC.

AIMS

To evaluate the efficacy of combined FIT and volatile organic compounds (VOC) in the detection of CRC within symptomatic populations.

METHODS

Systematic reviews on the diagnostic accuracy of FIT and VOC, for the detection of CRC, were updated. Meta-analyses were performed adopting a bivariate model for sensitivity and specificity. Clinical utility of combined FIT and VOC was estimated using Fagan's nomogram. Post-test probability of FIT negatives was used as a pre-test probability for VOC.

RESULTS

The pooled sensitivity and specificity of FIT at 10 µg/g faeces, for the detection of CRC, were 0.914 (95% confidence interval [CI] = 0.894-0.936) and 0.783 (CI = 0.850-0.696), respectively. For VOC, the sensitivity was 0.837 (CI = 0.781-0.881) and the specificity was 0.803 (CI = 0.870-0.712). The area under the curve for FIT and VOC were 0.926 and 0.885, respectively. In a population with 5% CRC prevalence, the estimated probability of having CRC following a negative FIT was 0.5% and following both negative FIT and VOC was 0.1%.

CONCLUSIONS

In a FIT-negative symptomatic population, VOC can be a good test to rule-out the presence of CRC. The estimated probability reduction by 0.4% when both tests being negative offers adequate safety netting in primary care for the exclusion of CRC. The number needed to colonoscope to identify one CRC is eight if either FIT or VOC positive. Cost-effectiveness and clinical accuracy of this approach will need further evaluation.

摘要

背景

粪便免疫化学测试(FIT)作为一种排除结直肠癌(CRC)的有效检测方法正在兴起。然而,FIT 的准确性取决于所应用的截止值。增加一种低成本的测试方法可以进一步提高 CRC 的检出率。

目的

评估联合 FIT 和挥发性有机化合物(VOC)在症状人群中检测 CRC 的效果。

方法

更新了关于 FIT 和 VOC 检测 CRC 的诊断准确性的系统评价。采用双变量模型进行了荟萃分析,以获得敏感性和特异性。使用 Fagan 的列线图评估联合 FIT 和 VOC 的临床实用性。FIT 阴性的后验概率被用作 VOC 的先验概率。

结果

粪便中 10μg/g 粪便的 FIT 检测 CRC 的合并敏感性和特异性分别为 0.914(95%置信区间 [CI] = 0.894-0.936)和 0.783(CI = 0.850-0.696)。对于 VOC,敏感性为 0.837(CI = 0.781-0.881),特异性为 0.803(CI = 0.870-0.712)。FIT 和 VOC 的曲线下面积分别为 0.926 和 0.885。在 5%CRC 患病率的人群中,FIT 阴性后发生 CRC 的概率估计为 0.5%,而 FIT 和 VOC 均阴性后发生 CRC 的概率估计为 0.1%。

结论

在 FIT 阴性的症状人群中,VOC 可以作为排除 CRC 的良好检测方法。当两项测试均为阴性时,估计减少的概率为 0.4%,这在初级保健中为排除 CRC 提供了足够的安全网。如果 FIT 或 VOC 阳性,则需要进行 8 次结肠镜检查才能识别出一个 CRC。需要进一步评估这种方法的成本效益和临床准确性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验